(Q44062243)

29 November 2017

One-year open-label trial of thalidomide in ankylosing spondylitis (English)

1 reference

29 November 2017

0 references

Feng Huang

1

1 reference

29 November 2017

Jieruo Gu

2

1 reference

29 November 2017

Wei Zhao

3

1 reference

29 November 2017

Jian Zhu

4

1 reference

29 November 2017

Jianglin Zhang

5

1 reference

29 November 2017

David Tak Yan Yu

6

1 reference

29 November 2017

1 June 2002

1 reference

29 November 2017

Arthritis & Rheumatology

1 reference

29 November 2017

47

1 reference

29 November 2017

249-254

1 reference

29 November 2017

3

1 reference

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

29 November 2017

1 reference

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

21 January 2018

1 reference

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

21 January 2018

1 reference

Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation

21 January 2018

1 reference

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

21 January 2018

1 reference

The role of thalidomide in the treatment of rheumatic disease

21 January 2018

1 reference

Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.10396

1 reference

29 November 2017

1 reference